Therapix Biosciences (Israel) Probability of Target Price Finishing Over Current Price

    TRPX -- Israel Stock  

    null 33.70  0.70  2.12%

    Therapix Biosciences probability of target price tool provides mechanism to make assumptions about upside and downside potential of Therapix Biosciences Ltd performance during a given time horizon utilizing its historical volatility. Please specify Therapix Biosciences time horizon, a valid symbol (red box) and a target price (blue box) you would like Therapix Biosciences odds to be computed. Also please take a look at World Market Map.
    Horizon     30 Days    Login   to change
    Symbol:
    Refresh Odds

    Therapix Biosciences Target Price Odds to finish over

    Current PriceHorizonTarget PriceOdds to move above current price in 30 days
     33.70 30 days 33.70  ABOUT 14.77%
    Based on normal probability distribution, the odds of Therapix Biosciences to move above current price in 30 days from now is about 14.77% (This Therapix Biosciences Ltd probability density function shows the probability of Therapix Biosciences Stock to fall within a particular range of prices over 30 days) .
    Assuming 30 trading days horizon, Therapix Biosciences has beta of 0.0 . This entails unless we do not have required data, the returns on DOW and Therapix Biosciences are completely uncorrelated. Additionally Therapix Biosciences LtdIt does not look like Therapix Biosciences alpha can have any bearing on the equity current valuation.
     Therapix Biosciences Price Density 
     
          
    Current Price   Target Price   
    α
    Alpha over DOW
    =0.00
    β
    Beta against DOW=0.00
    σ
    Overall volatility
    =16.67
    Ir
    Information ratio =0.00

    Therapix Biosciences Alerts

    Therapix Biosciences Alerts and Suggestions

    Therapix Biosciences is not yet fully synchronised with the market data
    Therapix Biosciences generates negative expected return over the last 30 days
    Therapix Biosciences has high likelihood to experience some financial distress in the next 2 years
    The company reported revenue of . Net Loss for the year was (7.66 M).
    THERAPIX BIO has accumulated about 7.51 M in cash with (6.01 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.04.
    Also please take a look at World Market Map. Please also try Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
    Search macroaxis.com